Vanda Pharmaceuticals | VNDA - Le Chiffre D'Affaires De Vente





Ventes Changement Date
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Anika Therapeutics USD 30.62M 2.8M 2025-12
Arrowhead Research USD 75.23M 1.49M 2026-06
AstraZeneca USD 15.38B 90M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Eli Lilly USD 22.97B 3.17B 2026-06
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Halozyme Therapeutics USD 481M 104M 2026-06
Heron Therapeutics USD 40.59M 2.38M 2025-12
Insmed USD 425.49M 119.53M 2026-06
J&J USD 25.31B 1.21B 2026-06
Lexicon Pharmaceuticals USD 5.49M 8.69M 2025-12
Ligand Pharmaceuticals USD 83.7M 31.98M 2026-06
Merck USD 16.6B 310M 2026-06
Minerva Neurosciences USD 0 0 2024-09
Moderna USD 100M 289M 2026-06
Novartis USD 13.11B 750M 2026-03
Pfizer USD 15.03B 530M 2026-06
PTC Therapeutics USD 361M 88M 2026-06
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 11.95B 710M 2026-06
Takeda JPY 1.22T 130B 2026-06
Teva Pharmaceutical Industries USD 12.67B 900M 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Veracyte USD 150.32M 11.25M 2026-06